Ginsberg 1998.

Study characteristics
Methods	Design: parallel Duration: 4 weeks Assessment: baseline and post‐intervention Country: Belgium
Participants	Pain condition: fibromyalgia Population: people with fibromyalgia Minimum pain intensity: no Inclusion criteria Aged between 18 and 75 Fibromyalgia meeting the ACR 1990 criteria History of widespread pain for at least 3 months Pain in at least 11 of 18 specific tender points Exclusion criteria Physical health comorbidities Total participants randomised: 100 Age in years (mean): 39.8 Gender: 85/100 were female Pain duration in months (mean): 34.7
Interventions	Placebo n = 50 Inert Matched dosing Pirlindole 150 mg n = 50 Reversible MAOI Fixed dose
Outcomes	Pain intensity Mood AEs Withdrawal
Missing data methods	NR
Funding source	NR
Conflicts of interest	NR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation methods not specified
Allocation concealment (selection bias)	Unclear risk	Allocation procedures not specified
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	States double‐blind, but no information regarding study drugs' appearance
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Self‐reported outcomes from participants, but unsure of blinding
Incomplete outcome data (attrition bias) All outcomes	High risk	Completer analysis only. Unclear with number randomised, completer analysis and no clear explanation of when and who withdrew. Attrition Total: 39/100 (39.0%) Placebo: 22/44 (50.0%) Pirlindole 150 mg: 17/45 (37.8%)
Selective reporting (reporting bias)	Unclear risk	No protocol or trial registration found
Other bias	Low risk	No other sources of bias identified